ATP6V1B1

Across TCGA pan-cancer cohorts, ATP6V1B1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATP6V1B1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATP6V1B1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP6V1B1 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where ATP6V1B1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP6V1B1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.329	<.001	12	view →
PDAC	Male	All	+1.242	<.001	6	view →
LUAD	Female	All	−0.956	<.001	6	view →
HNSC	All	II,III,IV	−0.601	<.001	6	view →
LSCC	All	All	−0.427	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATP6V1B1–CCRCC

Open the CCRCC breakdown →